Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: Toward new candidates

Journal of Medicinal Chemistry

Volumn 52, Issue 2, 2009, Pages 259-266

  Viale, Maurizio ^a   Cordazzo, Cinzia ^b   Cosimelli, Barbara ^c   De Totero, Daniela ^a   Castagnola, Patrizio ^a   Aiello, Cinzia ^a   Severi, Elda ^b,c   Petrillo, Giovanni ^b   Cianfriglia, Maurizio ^d   Spinelli, Domenico ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 OXADIAZOLE DERIVATIVE; 5 METHYL 8H [1,4]THIAZINO[3.4 C][1,2,4]OXADIZOL 3 ONE DERIVATIVE; 8H [1,4]THIAZINO[3.4 C][1,2,4]OXADIAZOL 3 ONE DERIVATIVE; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DILTIAZEM DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; P GLYCOPROTEIN 170; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; DRUG POTENCY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; DILTIAZEM; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROSCOPY, FLUORESCENCE; P-GLYCOPROTEIN;

EID: 60549092933     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801195k     Document Type: Article

References (38)

1. Nadkar, A.; Pungaliya, C.; Drake, K.; Zajac, E.; Singhal, S. S.; Awasthi, S. Therapeutic Resistance in Lung Cancer. Expert Opin. Drug Metab. Toxicol. 2006, 2, 753-777.
2. Gatti, L.; Zunino, F. Overview of Tumor Cell Chemoresistance Mechanisms. Methods Mol. Med. 2005, 111, 127-148.
3. Zhao, R.; Goldman, I. D. Resistance to Antifolates. Oncogene 2003, 22, 7431-7457.
4. Litman, T.; Druley, T. E.; Stein, W. D.; Bates, S. E. From MDR to MXR: New Understanding of Multidrug Resistance Systems, Their Properties and Clinical Significance. Cell. Mol. Life Sci. 2001, 58. 931-959.
5. Dean, M.; Fojo, T.; Bates, S. Tumour Stem Cells and Drug Resistance. Nat. Rev. Cancer 2005, 5, 275-284.
6. Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol. Rev. 2006, 86, 1179-1236.
7. Aszalos, A. Drug-Drug Interactions Affected by the Transporter Protein, P-Glycoprotein (ABCB1, MDR1) II. Clinical Aspects. Drug Discovery Today 2007, 12, 838-843.
8. Li, X.; Li, J. P.; Yuan, H. Y.; Gao, X.; Qu, X. J.; Xu, W. F.; Tang, W. Recent Advances in P-Glycoprotein-Mediated Multidrug Resistance Reversal Mechanisms. Methods Find. Exp. Clin. Pharmacol. 2007, 29, 607-617.
9. Sharom, F. J. Shedding Light on Drug Transport: Structure and Function of the P-Glycoprotein Multidrug Transporter (ABCB1). Biochem. Cell Biol. 2006, 84, 979-992.
10. Litman, T.; Skovsgaard, T.; Stein, W. D. Pumping of Drugs by P-Glycoprotein: A Two-Step Process. J. Pharmacol. Exp. Ther. 2003, 307, 846-853.
11. Pérez-Tomás, R. Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment. Curr. Med. Chem. 2006, 13, 1859-1876.
12. Hirose, M.; Hosoi, E.; Hamano, S.; Jalili, A. Multidrug Resistance in Hematological Malignancy. J. Med. Invest. 2003, 50, 126-135.
13. Sonneveld, P. Multidrug Resistance in Haematological Malignancies. J. Intern. Med. 2000, 247, 521-534.
14. Scagliotti, G. V.; Novello, S.; Selvaggi, G. Multidrug Resistance in Non-Small-Cell Lung Cancer. Ann. Oncol. 1999, 10 (Suppl 5), S83-S86.
15. Kaye, S. B. Multidrug Resistance: Clinical Relevance in Solid Tumours and Strategies for Circumvention. Curr. Opin. Oncol. 1998, 10 (Suppl 1), S15-19.
16. Mechetner, E.; Kyshtoobayeva, A.; Zonis, S.; Kim, H.; Stroup, R.; Garcia, R.; Parker, R. J.; Fruehauf, J. P. Levels of Multidrug Resistance (MDR1) P-Glycoprotein Expression by Human Breast Cancer Correlate with In Vitro Resistance to Taxol and Doxorubicin. Clin. Cancer Res. 1998, 4, 389-398.
17. Lum, B. L.; Gosland, M. P.; Kaubisch, S.; Sikic, B. I. Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene. Pharmacotherapy 1993, 13, 88-109.
18. Avedaño, C.; Menéndez, J. C. Inhibitors of Multidrug Resistance to Antitumour Agents (MDR). Curr. Med. Chem. 2002, 9, 159-193.
19. Aouali, N.; Eddabra, L.; Macadré, J.; Morjani, H. Immunosuppressors and Reversion of Multidrug-Resistance. Crit. Rev. Oncol. Hematol. 2005, 56, 61-70.
20. Krishna, R.; Mayer, L. D. Multidrug Resistance (MDR) in Cancer. Mechanisms, Reversal Using Modulators of MDR, and the Role of MDR Modulators in Influencing the Pharmacokinetics of Anticancer Drugs. Eur. J. Pharm. Sci. 2000, 11, 265-283.
21. Balayssac, D.; Authier, N.; Cayre, A.; Coudore, F. Does Inhibition of P-Glycoprotein Lead to Drug-Drug Interactions? Toxicol. Lett. 2005, 156, 319-329.
22. Budriesi, R.; Cosimelli, B.; Ioan, P.; Lanza, C. Z.; Spinelli, D.; Chiarini, A. Cardiovascular Characterization of [1,4]Thiazino[3,4-c][1,2,4] oxadiazol- 1-one Derivatives: Selective Myocardial Calcium Channel Modulators. J. Med. Chem. 2002, 45, 3475-3481.
23. Budriesi, R.; Carosati, E.; Chiarini, A.; Cosimelli, B.; Cruciani, G.; Ioan, P.; Spinelli, D.; Spisani, R. A New Class of Selective Myocardial Calcium Channel Modulators. 2. Role of the Acetal Chain in Oxadiazol-3-one Derivatives. J. Med. Chem. 2005, 48, 2445-2456.
24. Abu-Qare, A. W.; Elmasry, E.; Abou-Donia, M. B. A Role for P-Glycoprotein in Environmental Toxicology. J. Toxicol. Environ. Health, Part B 2003, 6, 279-288.
25. Ferry, D. R.; Traunecker, H.; Kerr, D. J. Clinical Trials of P-Glycoprotein Reversal in Solid Tumors. Eur. J. Cancer 1996, 32A, 1070-1081.
26. Fischer, V.; Rodríguez-Gascón, A.; Heitz, F.; Tynes, R.; Hauck, C.; Cohen, D.; Vickers, A. E. The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A. Drug Metab. Dispos. 1998, 26, 802-811.
27. Wandel, C.; Kim, R. B.; Kajiji, S.; Guengerich, P.; Wilkinson, G. R.; Wood, A. J. P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies. Cancer Res. 1999, 59, 3944-3948.
28. Qi, J.; Yang, C. Z.; Wang, C. Y.; Wang, S. B.; Yang, M.; Wang, J. H. Function and Mechanism of Pyronaridine: a New Inhibitor of P-Glycoprotein- Mediated Multidrug Resistance. Acta Pharmacol. Sin. 2002, 23, 544-550.
29. Beck, W. T.; Qian, X. D. Photoaffinity Substrates for P-Glycoprotein. Biochem. Pharmacol. 1992, 43, 89-93.
30. Martin, C.; Berridge, G.; Higgins, C. F.; Mistry, P.; Charlton, P.; Callaghan, R. Communication Between Multiple Drug Binding Sites on P-Glycoprotein. Mol. Pharmacol. 2000, 58, 624-632.
31. Lipinski, C. A.; Lombardo, B.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
32. Spinelli, D.; Mugnoli, A.; Andreani, A.; Rambaldi, M.; Frascari, S. A New Ring Transformation: Conversion of 6-p-Clorophenyl-3-methyl-5- nitrosoimidazo[2,1-b]thiazole into 6-p-Chlorophenyl-8-hydroxy-5- methyl-3-oxo-1,2,4-oxadiazolo[3,4-c][1,4]thiazine by the Action of Mineral Acids. Chem. Soc. Chem. Commun. 1992, 1394-1395.
33. Andreani, A.; Billi, R.; Cosimelli, B.; Mugnoli, A.; Rambaldi, M.; Spinelli, D. Ring- ring interconversion: the rearrangement of 6(4-chlorophenyl)-3-methyl-5-nitrosoimidazo[2,1-b][1,3]thiazole into 8-(4-chlorophenyl)-8-hydroxy-5-methyl-8H -[1,4]thiazino[3,4-c][1,2,4] oxadiazol-3-one. Elucidation of the reaction product through spectroscopic and X-ray crystal structure analysis. J. Chem. Soc., Perkin Trans. 2 1997, 2407-2419.
34. Billi, R.; Cosimelli, B.; Spinelli, D.; Rambaldi, M. Ring-ring Interconversions. Part 2. Effect of the Substituent on the Rearrangement of 6-Aryl-3-methyl-5-nitrosoimidazo[2,1-b][1,3]thiazoles into 8-Aryl-8-hydroxy-5-methyl-8H-[1,4]thiazino[3,4-c][1,2,4] oxadiazol-3-ones. Tetrahedron 1999, 55, 5433-5440.
35. Carosati, E.; Cruciani, G.; Chiarini, A.; Budriesi, R.; Ioan, P.; Spisani, R.; Spinelli, D.; Cosimelli, B.; Fusi, F.; Frosini, M.; Matucci, R.; Gasparrini, F.; Ciogli, A.; Stephens, P. J.; Devlin, F. J. Calcium Channel Antagonists Discovered by a Multidisciplinary Approach. J. Med. Chem. 2006, 49, 5206-5216.
36. Stephens, P. J.; Devlin, F. J.; Gasparrini, F.; Ciogli, A.; Spinelli, D.; Cosimelli, B. Determination of the Absolute Configuration of a Chiral Oxadiazol-3-one Calcium Channel Blocker, Resolved Using Chiral Chromatography, via Concerted Density Functional Theory Calculations of Its Vibrational Circular Dicroism, Electronic Circular Dicroism, and Optical Rotation. J. Org. Chem. 2007, 72, 4707-4715.
37. Hussain, R. F.; Nouri, A. M. E.; Oliver, R. T. D. A New Approach for Measurement of Cytotoxicity Using Colorimetric Assay. J. Immunol. Methods 1993, 160, 89-96.
38. Cianfriglia, M.; Willingham, M. C.; Tombesi, M.; Scagliotti, G. V.; Frasca, G.; Chersi, A. P-Glycoprotein Epitope Mapping. I. Identification of A Linear Human-Specific Epitope in the Fourth Loop of the P-Glycoprotein Extracellular Domain by MM4.17 Murine Monoclonal Antibody to Human Multi-Drug-Resistant Cells. Int. J. Cancer 1994, 56, 153-160.